JPS5843926A
(ja)
*
|
1981-09-08 |
1983-03-14 |
Suntory Ltd |
選択性制癌剤
|
FR2523445A1
(fr)
*
|
1982-03-17 |
1983-09-23 |
Sanofi Sa |
Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
|
DE3369466D1
(en)
*
|
1982-05-12 |
1987-03-05 |
Harvard College |
Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
|
US4520226A
(en)
*
|
1982-07-19 |
1985-05-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
|
JPS5990052A
(ja)
*
|
1982-11-16 |
1984-05-24 |
Katsu Taniguchi |
モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
|
US4916213A
(en)
*
|
1983-02-22 |
1990-04-10 |
Xoma Corporation |
Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
|
US4591572A
(en)
*
|
1983-04-01 |
1986-05-27 |
Sloan-Kettering Institute For Cancer Research |
Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
|
JPS59186924A
(ja)
*
|
1983-04-08 |
1984-10-23 |
Kureha Chem Ind Co Ltd |
ヒト免疫グロブリン結合抗腫瘍剤
|
US4664911A
(en)
*
|
1983-06-21 |
1987-05-12 |
Board Of Regents, University Of Texas System |
Immunotoxin conjugates employing toxin B chain moieties
|
GB2142428A
(en)
*
|
1983-06-23 |
1985-01-16 |
Erba Farmitalia |
Adenocarcinoma related antigenic determinants and antibodies specific thereto
|
FR2547731A1
(fr)
*
|
1983-06-27 |
1984-12-28 |
Centre Nat Rech Scient |
Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
|
GB2148299B
(en)
*
|
1983-09-01 |
1988-01-06 |
Hybritech Inc |
Antibody compositions of therapeutic agents having an extended serum half-life
|
US4545985A
(en)
*
|
1984-01-26 |
1985-10-08 |
The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services |
Pseudomonas exotoxin conjugate immunotoxins
|
FR2570278B1
(fr)
*
|
1984-09-14 |
1987-02-13 |
Pasteur Institut |
Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
|
AU585940B2
(en)
*
|
1984-09-25 |
1989-06-29 |
Xoma Corporation |
Lectin immunotoxins
|
US4590071A
(en)
*
|
1984-09-25 |
1986-05-20 |
Xoma Corporation |
Human melanoma specific immunotoxins
|
EP0232447A1
(en)
*
|
1986-02-13 |
1987-08-19 |
Xoma Corporation |
Lectin immunotoxins
|
FR2573656B1
(fr)
*
|
1984-11-29 |
1987-02-27 |
Sanofi Sa |
Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
|
US4851510A
(en)
*
|
1984-11-30 |
1989-07-25 |
Wadley Technologies, Inc. |
Monoclonal antibodies to novel melanoma-associated antigens
|
US5256413A
(en)
*
|
1985-01-08 |
1993-10-26 |
The General Hospital Corporation |
Method and use for site-specific activation of substances
|
AT384549B
(de)
*
|
1985-01-08 |
1987-11-25 |
Strasser Engelbert |
Verfahren zur herstellung einer vaccine
|
FR2577135B1
(fr)
*
|
1985-02-13 |
1989-12-15 |
Sanofi Sa |
Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
|
US4744981A
(en)
*
|
1985-10-17 |
1988-05-17 |
Neorx Corporation |
Trichothecene antibody conjugates
|
ATE87318T1
(de)
*
|
1985-11-29 |
1993-04-15 |
Consolidated Pharmaceuticals L |
Ricin-antikoerper-konjugate.
|
US4831122A
(en)
*
|
1986-01-09 |
1989-05-16 |
Regents Of The University Of Minnesota |
Radioimmunotoxins
|
US4689401A
(en)
*
|
1986-03-06 |
1987-08-25 |
Cetus Corporation |
Method of recovering microbially produced recombinant ricin toxin a chain
|
USRE38008E1
(en)
|
1986-10-09 |
2003-02-25 |
Neorx Corporation |
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
US4771128A
(en)
*
|
1986-10-10 |
1988-09-13 |
Cetus Corporation |
Method of purifying toxin conjugates using hydrophobic interaction chromatography
|
US5009995A
(en)
*
|
1986-10-27 |
1991-04-23 |
Sloan-Kettering Institute For Cancer Research |
Monoclonal antibodies to melanoma cells
|
US5582862A
(en)
|
1988-04-04 |
1996-12-10 |
General Hospital Corporation |
Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
|
US5372812A
(en)
*
|
1988-04-04 |
1994-12-13 |
The General Hospital Corporation |
Composition and method for acceleration of clot lysis
|
US5811265A
(en)
*
|
1988-08-19 |
1998-09-22 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5609869A
(en)
*
|
1988-08-19 |
1997-03-11 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5252713A
(en)
*
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
US5171563A
(en)
*
|
1988-09-30 |
1992-12-15 |
Neorx Corporation |
Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
|
IE910820A1
(en)
*
|
1990-03-22 |
1991-09-25 |
Sloan Kettering Inst Cancer |
Gp75 as a tumor vaccine for melanoma
|
ZA912490B
(en)
*
|
1990-04-19 |
1992-12-30 |
Res Dev Foundation |
Antibody conjugates for treatment of neoplastic disease
|
US5981194A
(en)
*
|
1992-07-10 |
1999-11-09 |
University Of British Columbia |
Use of p97 and iron binding proteins as diagnostic and therapeutic agents
|
US5690935A
(en)
*
|
1995-01-13 |
1997-11-25 |
Regents Of The University Of Minnesota |
Biotherapy of cancer by targeting TP-3/P80
|
EP0873363B1
(en)
|
1995-06-14 |
2010-10-06 |
The Regents of The University of California |
High affinity human antibodies to tumor antigens
|
JP2001502895A
(ja)
*
|
1996-09-20 |
2001-03-06 |
ザ・ジェネラル・ホスピタル・コーポレイション |
アルファ―2―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
|
US6869604B1
(en)
*
|
1998-03-27 |
2005-03-22 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant anti-tumor RNAse
|
WO1999058139A2
(en)
*
|
1998-05-08 |
1999-11-18 |
The Regents Of The University Of California |
Methods for detecting and inhibiting angiogenesis
|
US6852318B1
(en)
|
1998-05-08 |
2005-02-08 |
The Regents Of The University Of California |
Methods for detecting and inhibiting angiogenesis
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
ATE536550T1
(de)
|
2000-10-06 |
2011-12-15 |
Life Technologies Corp |
Halbleiter nanokristalle enthaltende transfektibare mizellen
|
EP2381116A1
(en)
|
2000-11-16 |
2011-10-26 |
California Institute of Technology |
Apparatus and methods for conducting assays and high throughput screening
|
ZA200305980B
(en)
*
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
US6955888B2
(en)
*
|
2001-06-11 |
2005-10-18 |
Xenoport |
Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
|
US7101977B2
(en)
|
2001-07-17 |
2006-09-05 |
Research Development Foundation |
Therapeutic agents comprising pro-apoptotic proteins
|
EP1463796B1
(en)
|
2001-11-30 |
2013-01-09 |
Fluidigm Corporation |
Microfluidic device and methods of using same
|
US20030158254A1
(en)
*
|
2002-01-24 |
2003-08-21 |
Xenoport, Inc. |
Engineering absorption of therapeutic compounds via colonic transporters
|
US20030158089A1
(en)
*
|
2002-01-24 |
2003-08-21 |
Xenoport, Inc. |
Administrative agents via the SMVT transporter
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US20030228619A1
(en)
*
|
2002-06-10 |
2003-12-11 |
Xenoport, Inc. |
Peptide nucleic acids as tags in encoded libraries
|
AU2003275985A1
(en)
*
|
2002-06-12 |
2003-12-31 |
Research Development Foundation |
Immunotoxin as a therapeutic agent and uses thereof
|
PT1530482E
(pt)
|
2002-07-18 |
2014-01-15 |
Helix Biopharma Corp |
Utilização de urease para inibição de crescimento de células cancerigenas
|
US20040161424A1
(en)
*
|
2002-10-08 |
2004-08-19 |
Xenoport |
Human organic solute transporters
|
WO2006102264A1
(en)
|
2005-03-18 |
2006-09-28 |
Fluidigm Corporation |
Thermal reaction device and method for using the same
|
JP5419248B2
(ja)
|
2003-04-03 |
2014-02-19 |
フルイディグム コーポレイション |
マイクロ流体装置およびその使用方法
|
NZ548256A
(en)
|
2004-02-02 |
2010-02-26 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
KR20070039593A
(ko)
|
2004-07-21 |
2007-04-12 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
|
JP2008520963A
(ja)
*
|
2004-11-16 |
2008-06-19 |
シーナ・キャンサー・ダイアグノスティクス・リミテッド |
サンプル中の分析物を検出する方法
|
CN102719366B
(zh)
*
|
2004-12-22 |
2014-07-16 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
CN103690936A
(zh)
|
2004-12-22 |
2014-04-02 |
Ambrx公司 |
经修饰的人类生长激素
|
CA2927595C
(en)
|
2004-12-22 |
2023-01-31 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
WO2006073846A2
(en)
|
2004-12-22 |
2006-07-13 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
BRPI0519170A8
(pt)
|
2004-12-22 |
2018-05-08 |
Ambrx Inc |
formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
|
JP2008528633A
(ja)
*
|
2005-02-01 |
2008-07-31 |
リサーチ ディベロップメント ファウンデーション |
Blysレセプターを標的化するためのblys融合タンパク質およびb細胞増殖性疾患の処置方法
|
AU2006255122B2
(en)
*
|
2005-06-03 |
2010-10-21 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
CN103103238B
(zh)
*
|
2005-08-18 |
2016-08-10 |
Ambrx公司 |
一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
|
AU2006311568B2
(en)
*
|
2005-11-08 |
2010-11-11 |
Ambrx, Inc. |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
AU2006315347A1
(en)
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
KR101423898B1
(ko)
*
|
2005-12-14 |
2014-07-28 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
|
CA2663083A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
NZ574960A
(en)
*
|
2006-09-08 |
2012-02-24 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells
|
WO2008030613A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
JP5650406B2
(ja)
*
|
2007-03-07 |
2015-01-07 |
ユーティーアイ リミテッド パートナーシップ |
自己免疫状態の予防および治療のための組成物および方法
|
WO2008121563A2
(en)
|
2007-03-30 |
2008-10-09 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
NZ580686A
(en)
*
|
2007-05-02 |
2012-11-30 |
Ambrx Inc |
Modified interferon beta polypeptides and their uses
|
CA2699394C
(en)
|
2007-09-17 |
2020-03-24 |
The Regents Of The University Of California |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
AU2008302111B2
(en)
|
2007-09-21 |
2014-04-24 |
The Regents Of The University Of California |
Targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
CN103694337B
(zh)
|
2008-02-08 |
2016-03-02 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
IL198123A0
(en)
|
2008-04-18 |
2009-12-24 |
Snecma Propulsion Solide |
A heat treatment oven with inductive heating
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
EP3225248B1
(en)
*
|
2008-07-23 |
2023-06-07 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
CA2738033C
(en)
*
|
2008-09-26 |
2019-11-26 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
CA2737026C
(en)
|
2008-09-26 |
2019-12-24 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
CN102438580B
(zh)
|
2009-02-06 |
2015-06-17 |
加利福尼亚大学董事会 |
钙结合剂诱导毛发生长和/或甲生长
|
MX349301B
(es)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Polipéptidos de somatotropina bovina modificados y sus usos.
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
DK2605789T3
(da)
|
2010-08-17 |
2019-09-16 |
Ambrx Inc |
Modificerede relaxinpolypeptider og anvendelser deraf
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
EP2616045B1
(en)
|
2010-09-15 |
2017-10-25 |
Randall J. Mrsny |
Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
AU2011310513C1
(en)
|
2010-09-29 |
2016-06-02 |
Uti Limited Partnership |
Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
|
US9511151B2
(en)
|
2010-11-12 |
2016-12-06 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of cancer
|
CN105388287A
(zh)
|
2011-03-11 |
2016-03-09 |
内布拉斯加大学董事委员会 |
冠状动脉疾病的生物标志物
|
DK2694095T3
(en)
|
2011-04-05 |
2018-05-28 |
Longevity Biotech Inc |
COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
|
MX371526B
(es)
|
2011-05-27 |
2020-01-31 |
Ambrx Inc |
Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
|
KR20200128601A
(ko)
|
2011-05-27 |
2020-11-13 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
|
CN104470536A
(zh)
|
2012-03-03 |
2015-03-25 |
免疫基因公司 |
工程化的抗体-干扰素突变体融合分子
|
US10988516B2
(en)
|
2012-03-26 |
2021-04-27 |
Uti Limited Partnership |
Methods and compositions for treating inflammation
|
AU2013270686B2
(en)
|
2012-06-07 |
2016-11-10 |
Ambrx, Inc. |
Prostate-specific membrane antigen antibody drug conjugates
|
WO2013188740A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
CN111499684A
(zh)
|
2012-06-19 |
2020-08-07 |
Ambrx公司 |
抗cd70抗体药物结合物
|
US9603948B2
(en)
|
2012-10-11 |
2017-03-28 |
Uti Limited Partnership |
Methods and compositions for treating multiple sclerosis and related disorders
|
WO2014145718A2
(en)
|
2013-03-15 |
2014-09-18 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
US11559580B1
(en)
|
2013-09-17 |
2023-01-24 |
Blaze Bioscience, Inc. |
Tissue-homing peptide conjugates and methods of use thereof
|
US10519247B2
(en)
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
WO2015063616A2
(en)
|
2013-11-04 |
2015-05-07 |
Uti Limited Partnership |
Methods and compositions for sustained immunotherapy
|
FR3018526B1
(fr)
|
2014-03-14 |
2021-06-11 |
Herakles |
Installation de densification cvi comprenant une zone de prechauffage a forte capacite
|
AU2015255834B2
(en)
|
2014-05-07 |
2020-05-21 |
Applied Molecular Transport Llc |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
MX2017004947A
(es)
|
2014-10-24 |
2017-06-29 |
Bristol Myers Squibb Co |
Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
|
AU2016275312B2
(en)
|
2015-05-06 |
2021-12-23 |
Uti Limited Partnership |
Nanoparticle compositions for sustained therapy
|
KR20180077271A
(ko)
|
2015-11-03 |
2018-07-06 |
암브룩스, 인코포레이티드 |
항-cd3-폴레이트 컨쥬게이트 및 이의 용도
|
PT3383920T
(pt)
|
2015-11-30 |
2024-04-15 |
Univ California |
Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
|
EP3442996A4
(en)
|
2016-04-12 |
2019-11-27 |
Blaze Bioscience, Inc. |
METHODS OF TREATMENT INVOLVING CHLOROTOXIN CONJUGATES
|
AU2017250359B2
(en)
|
2016-04-15 |
2022-06-16 |
Blaze Bioscience, Inc. |
Methods of treating breast cancer
|
US11434301B2
(en)
|
2016-11-11 |
2022-09-06 |
The Regents Of The University Of California |
Anti-CD46 antibodies and methods of use
|
US20180163270A1
(en)
|
2016-12-12 |
2018-06-14 |
Cepheid |
Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
|
US11186622B2
(en)
|
2017-01-05 |
2021-11-30 |
The Regents Of The University Of California |
PAC1 receptor agonists (MAXCAPS) and uses thereof
|
KR102670432B1
(ko)
|
2017-02-08 |
2024-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
|
WO2019173787A1
(en)
|
2018-03-08 |
2019-09-12 |
Applied Molecular Transport Inc. |
Toxin-derived delivery constructs for oral delivery
|
CN112105376A
(zh)
|
2018-03-08 |
2020-12-18 |
应用分子运输公司 |
用于经口递送的毒素衍生的递送构建体
|
CN117924503A
(zh)
|
2018-03-29 |
2024-04-26 |
Ambrx公司 |
人源化抗***特异性膜抗原(psma)抗体药物缀合物
|
BR112021003843A2
(pt)
|
2018-08-28 |
2021-05-25 |
Ambrx, Inc. |
biconjugados de folato de anticorpo anti-cd3 e seus usos
|
KR20210057124A
(ko)
|
2018-09-11 |
2021-05-20 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 용도
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
AU2020223031A1
(en)
|
2019-02-12 |
2021-08-19 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-TLR agonist conjugates
|
BR112022002962A2
(pt)
|
2019-08-16 |
2022-07-05 |
Applied Molecular Transport Inc |
Composições, formulações e produção e purificação de interleucina
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
CN115243726A
(zh)
|
2020-03-11 |
2022-10-25 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其使用方法
|
CN116419747A
(zh)
|
2020-08-07 |
2023-07-11 |
福蒂斯治疗公司 |
靶向cd46的免疫偶联物及其使用方法
|
EP4199968A1
(en)
|
2020-08-20 |
2023-06-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
MX2023011480A
(es)
|
2021-04-03 |
2023-12-06 |
Ambrx Inc |
Conjugados anticuerpo anti-her2-fármaco y usos de estos.
|
WO2024077277A1
(en)
|
2022-10-07 |
2024-04-11 |
Ambrx, Inc. |
Drug linkers and antibody conjugates thereof
|